1. Home
  2. BLNK vs PMVP Comparison

BLNK vs PMVP Comparison

Compare BLNK & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.83

Market Cap

80.9M

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.50

Market Cap

73.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
PMVP
Founded
2009
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.9M
73.1M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
PMVP
Price
$0.83
$1.50
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$1.95
N/A
AVG Volume (30 Days)
2.5M
447.8K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
61.22
N/A
EPS
N/A
N/A
Revenue
$126,197,000.00
N/A
Revenue This Year
$5.71
N/A
Revenue Next Year
$19.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.83
52 Week High
$2.65
$1.88

Technical Indicators

Market Signals
Indicator
BLNK
PMVP
Relative Strength Index (RSI) 68.40 59.40
Support Level $0.63 $1.37
Resistance Level $0.97 $1.53
Average True Range (ATR) 0.06 0.07
MACD 0.03 0.02
Stochastic Oscillator 91.91 89.30

Price Performance

Historical Comparison
BLNK
PMVP

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: